🧬 AI-Powered Antibody Design Platform

AI-Powered Antibody Design for Precision Medicine

The only platform that designs antibodies from amino acid sequence alone. No crystal structure. No animal immunization. Validated candidates in ~30 days.

Schedule a Demo Explore Products
10,000×
Faster than AlphaFold
80%
Cost Reduction
40%
Wet-Lab Hit Rate
The Problem

Traditional Drug Discovery is Broken

Slow, expensive, and plagued by high failure rates

10–15 Yrs
Average time from target to market
$2.6B
Average cost per approved drug
<10%
Clinical trial success rate
75% of disease-relevant proteins remain "undruggable" because no 3D structural data exists. Pharmaceutical companies are spending more and discovering less.
Product Lines

Four Integrated Solutions

Powered by AINN-P1 Biological Sequence Foundation Model (167M parameters, 53M+ sequences)

Therapeutics

Revive Rx

AI-Driven Drug Rescue

Converting pharma losses into first-in-class assets. 90% of Phase I drugs fail — each represents $50–$500M in sunk cost. Revive Rx rescues these written-off assets with AI-driven molecular redesign at 1–10% of original cost.

$2M
Stage I Fee
27×
ROI
3 Mo
Delivery
Therapeutics

Target Rx

De Novo Biological Drug Design

First-in-class biological targets delivered in weeks, not years. 75% of drug targets remain unexplored. SentinusAI compresses target design to 1 week and wet lab validation to 3 weeks — at a price early biotech can afford.

$50–250K
Per Project
500+
Targets
1 Mo
Delivery
Diagnostics

Revive Dx

Diagnostic Ab Redesign

Optimize CDx antibodies for oncology panels and metabolic biomarker detection. AI-driven optimization delivers superior sensitivity and specificity for FDA-mandated companion diagnostics.

$20–100K
Per Engagement
FDA
CDx Path
18 Mo
CDx Timeline
Diagnostics

Target Dx

IVD & Companion Diagnostics

De novo diagnostics that transform empirical prescribing into targeted therapy. Full 18-month development arc from AI discovery through independent validation to CDx licensing.

€50–150M
CDx License
€50M+
License Value
$876K
Dev Cost
Scientific Validation

Peer-Reviewed Results

Binding affinities confirmed by SPR, BLI, and ELISA in independent partner laboratories

📄 Read the Paper in Nature Scientific Reports →
IL-13 × TSLP Bispecific
Phase I Trial
In Human Dosing
Respiratory
SARS-CoV-2
Sub-nM
269× improvement
Infectious Disease
CD19
28.3 pM
31.7× improvement
Oncology
IL-15
39.2 pM
12.5× improvement
Immuno-Oncology
Desmoglein-1
14.5 nM
14.6× improvement
Autoimmune
Competitive Edge

Why SentinusAI® Wins

A direct comparison on the dimensions that matter most

Capability SentinusAI® AlphaFold / ESM Absci / BigHat Phage Display
Designs new antibodies? ✓ De novo design ✗ Structure only Needs 3D structure Random screening
Works without crystal structure? ✓ Sequence-only N/A ✗ Structure-dependent N/A
Computational efficiency ✓ 10,000× efficient Massive GPU cost GPU-intensive Wet-lab only
Whole-genome screening? ✓ 10¹⁰ sequences ✗ Single protein ✗ Limited ✗ No
Speed to candidates ✓ ~30 days N/A 3–6 months 6–12 months
Addresses 75% undruggable? ✓ Yes ✗ No ✗ No ✗ No
Revenue-generating today? ✓ $602K (2024) Open-source Pre-revenue Commodity
Leadership

World-Class Team

Deep expertise in AI, drug discovery, and commercial execution

Dr. Lurong Pan

Dr. Lurong Pan

Founder & CEO

16+ years computational chemistry, AI, and therapeutic design. Senior Investigator at Gates Foundation/GHDDI. Built one of Asia's largest AI-driven infectious disease platforms. PhD Chemistry (UAB), MS AI (Georgia Tech). Merck Pandemic Award. 100+ publications.

David Donaldson

David Donaldson

Chief Financial Officer

Oxford (Jurisprudence), FCA. 20+ years investment banking at Salomon Brothers, Morgan Stanley, Deutsche Bank. Founding member, Emirates Investment Authority (UAE sovereign wealth fund). Founded 4 companies across Dubai, Abu Dhabi, Riyadh.

Dr. Rita Boukamel

Dr. Rita Boukamel

Chief Commercial Officer

PhD Biochemistry (Strasbourg), postdoc ETH Zürich. 15+ years diagnostics commercial leadership at Roche, GE Healthcare, and Accelerate Diagnostics (SVP, Head of EMEA). Built networks across 40+ countries in Europe, ME, and Africa.

Dr. Sheng Ding

Dr. Sheng Ding

Professor, UCSF

Founding Dean, Tsinghua. Director, GHDDI. Co-founder Fate Therapeutics (FATE), Tenaya (TNYA), Retro Biosciences. 300+ publications. Pioneer in chemical control of stem cell fate.

Dr. Kyle Brewer

Dr. Kyle Brewer

Associate Director, Stanford

Co-founder ETTA Biotech. Former OpenAI (biological model tuning). PhD Molecular Biophysics, UT Southwestern. Expert in advanced drug delivery and regenerative biomaterials.

Dr. Murat Tanik

Dr. Murat Tanik

Wallace R. Bunn Chair, UAB

Co-director Integrated Systems Center. Co-founder, Society for Design and Process Science. PhD Computer Science, Texas A&M. AI foundations underpinning AINN-P1 architecture.

Traction

Proven Market Demand

60+
Validated Projects
20+
Fee-for-Service Contracts
100+
Pipeline Engagements
$602K
2024 Revenue
$122K
2024 Net Income
Pfizer Bayer Yale University Weill Cornell Leyden Labs MBL / JSR

Ready to Transform Drug Discovery?

Join Pfizer, Bayer, Yale, and 60+ organizations using SentinusAI®

Contact Us Today